ANALYSIS: Myriad, Mayo fuel biopharma patent rejections
This article was originally published in Scrip
Rejections by the US Patent and Trademark Office (US PTO) of applications for biotechnology-related inventions appear to significantly be on the rise after new examination guidelines were put in place following the Supreme Court's rulings in Association for Molecular Pathology v Myriad Genetics and Mayo Collaborative Services v Prometheus Laboratories – two decisions that sent shockwaves through the industry – according to a new report.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.